Loading…
For healthy adults at standard weekly doses: Partially Supported. For those with kidney issues or active infection: not without a physician.
Rapamycin is the most-studied longevity drug in mice and the most contested in humans. Mouse evidence for lifespan extension is strong across multiple lab sites (Harrison 2009, NIA ITP). Human evidence is preliminary — the PEARL trial showed acceptable safety at weekly doses but did not yet demonstrate aging-marker improvement.
For healthy adults, weekly low-dose rapamycin under physician supervision is reasonable to consider. For most people, it's premature. The strongest evidence-based reading is "wait for the human longevity trials."
Audited Peter Attia's rapamycin podcast (14 claims) and Bryan Johnson's Blueprint rapamycin pages (23 claims). Cross-checked against Harrison et al. (2009) and Mannick et al. (2024) PEARL trial.
Immunosuppressive at high doses. Active infection contraindicates. Drug-drug interactions extensive. Compounded "weekly low-dose" protocols circulating on social media often lack physician oversight — this is the failure mode we're flagging.
A human longevity RCT (one is in planning, ~2028 readout). Updated safety surveillance from active dosers. New head-to-head with calorie restriction or other geroprotective candidates.
The effect size is large enough to matter clinically, not just statistically.
Mechanistic and trial evidence converge on a real, replicable effect.
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.
The intervention improves the primary outcome at standard doses in healthy adults.
Rapamycin raises fasting glucose and worsens insulin sensitivity in a meaningful subset of users.
Confounding and publication bias inflate the apparent benefit.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
Rapamycin slows wound healing enough to recommend pausing it around elective surgery.
Animal-model results don't translate to the human protocol being recommended.